Buccal drug delivery systems represent an innovative strategy for the administration of therapeutic agents via the oral mucosa. This approach bypasses the hepatic first‐pass metabolism, thereby ...

U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States for the treatment of seizure clusters in patients ages 2 to 5 ...